Aktie TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Aktien

IL0006290147

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Teva Pharmaceutical Industries : Immediate Report
Teva Pharmaceutical Industries : Immediate Report
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 883035 Aktie
  4. Aktie
  5. Nachrichten Teva Pharmaceutical Industries Limited
  6. Andere Sprachen